Join the club for FREE to access the whole archive and other member benefits.

Jonas Neher

Neuroscientist at DZNE

Jonas Neher Experience:

since 2017 Group leader (tenured) for Experimental Neuroimmunology, DZNE Tuebingen

2015 - 2017 Group leader for Experimental Neuroimmunology, Hertie Institute Tuebingen

2013 - 2015 Postdoctoral Researcher, Hertie Institute and DZNE Tuebingen

2011 - 2013 Roman Herzog Postdoctoral Fellow, Hertie Institute Tuebingen

2009 - 2011 Postdoctoral Researcher, University of Cambridge, UK

Honors and Awards

2011 Roman Herzog Postdoctoral Fellowship, Hertie Foundation

2005 Gates Cambridge Scholarship, Bill and Melissa Gates Foundation

2003 Dr. Anton-Keller Prize, University of Darmstadt

Areas of investigation/research focus

We recently demonstrated that microglia are capable of retaining a long-lasting epigenetic memory of peripheral inflammatory insults, which are known risk factors for late-onset AD. Importantly, this epigenetic memory altered how microglia responded to much later developing AD pathology and, in turn, affected how AD hallmarks developed in mouse models. These findings indicated that microglia are capable of “innate immune memory” (Wendeln et al., Nature, 2018). We are actively working on understanding the mechanisms of microglial epigenetic reprogramming in response to peripheral inflammation by analysing mouse and human tissue on a single cell basis, and by studying its effects on different forms of neurodegenerative diseases.

Thus, our main objective is to understand the pathogenic mechanism of Alzheimer’s disease and to develop new therapeutic interventions to treat this devastating disease.



Visit website: https://www.dzne.de/en/research/research-areas/fundamental-research/research-groups/neher/research-areasfocus/

 NeherJonas

See also: Institute German Center for Neurodegenerative Diseases (DZNE) - Research institute for neurodegenerative diseases.

Details last updated 16-Mar-2023

Jonas Neher News

Medin- amyloid-β aggregates could act an new targets to therapeutically treat Alzheimer's

Medin- amyloid-β aggregates could act an new targets to therapeutically treat Alzheimer's

German Center for Neurodegenerative Diseases (DZNE) - 17-Nov-2022

Medin deposits are indeed a cause of blood vessel damage, one of the causes of Alzheimer's disease